Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-FAN
2024-515497-26-00Phase 4Completed
- Sponsor
- Medical University of Graz
- Start
- Sep 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in exudative macular degeneration, sponsored by Medical University of Graz. Primary endpoint: Extension success rate. Started Sep 2024; status: completed.
02
Drugs
aflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2024-515497-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515497-26-00.